Review of observational data links semaglutide and tirzepatide to survival in breast cancer
Semaglutide linked to lower death rates in breast cancer patients compared to other diabetes drugs
This review synthesized observational, propensity-matched analyses of patients with pre-existing breast cancer.
In routine care, semaglutide users with breast cancer had significantly lower death rates and less metastatic disease than those on other co…
Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
Tirzepatide Saves Money and Health Over Semaglutide
This simulation modeling study using Phase-3 trial data evaluated tirzepatide versus semaglutide in individuals with obesity or overweight w…
Imagine standing in a doctor's office, facing a choice between two powerful weight-loss medicines.
Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes
New Obesity Drug Shows Stronger Weight Loss Than Popular Option
This narrative review evaluates tirzepatide versus semaglutide in individuals with obesity or type 2 diabetes mellitus.
This review shows that tirzepatide outperforms semaglutide for weight and blood sugar, but semaglutide currently has stronger proof for prot…
Tirzepatide shows greater lean body mass loss than semaglutide in first-episode GLP-1RA users with type 2 diabetes
One Weight-Loss Drug Trims More Muscle Than the Other — Here's Why
An observational study of 670,422 first-episode GLP-1RA users with type 2 diabetes found tirzepatide was associated with greater relative le…
Losing weight with a popular injection drug is not all equal — one drug may chip away at your muscle more than the other, which matters grea…
Oral denatonium acetate (ARD-101) reduced weight versus placebo in adults with obesity over 28 days
Could a Bitter Pill Trick Your Gut Into Feeling Full?
Randomized, placebo-controlled clinical studies and preclinical mouse studies evaluated oral denatonium acetate (ARD-101) in adults with obe…
A new gut-targeted pill tricks your intestines into feeling full, reducing hunger and helping adults lose weight in early human trials.
Subgroup analysis finds tirzepatide superior to dulaglutide for HbA1c and weight in type 2 diabetes
For people struggling with diabetes on dulaglutide, could switching drugs help?
This subgroup analysis of a phase IV RCT examined adults with type 2 diabetes inadequately controlled on dulaglutide.
Switching from dulaglutide to tirzepatide led to greater drops in blood sugar and body weight for adults with type 2 diabetes after 40 weeks…
Post hoc analysis links WHtR threshold to remission in obesity management with tirzepatide vs semaglutide
Could hitting specific weight targets help people feel better?
A post hoc analysis of the SURMOUNT-5 trial in participants with obesity found that 23.1%-33.9% on tirzepatide and 14.2%-20.7% on semaglutid…
People on tirzepatide who hit a waist-to-height ratio under 0.53 had more than double the odds of reaching remission compared to those who d…
Tirzepatide improves patient-reported physical function in adults with overweight or obesity
Tirzepatide may improve physical function for adults with overweight or obesity
A meta-analysis of 4,531 participants found that once-weekly tirzepatide 10 or 15 mg significantly improved physical function scores compare…
Adults with overweight or obesity taking tirzepatide reported better physical function scores on two questionnaires compared to those taking…